InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,792.80
(
0.00%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.31
(
-0.34%
)
Bitcoin
62,958.90
(
3.58%
)
Post# of 252595
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 220391

Tuesday, 08/21/2018 11:28:54 AM

Tuesday, August 21, 2018 11:28:54 AM

Post# of 252595
Transcript of ENTA FY3Q18 CC (8/7/18):

https://finance.yahoo.com/news/edited-transcript-enta-earnings-conference-195436339.html

[Jay Luly, CEO]: First…I want to comment on our increasing royalty revenue from AbbVie related to MAVIRET, currently the best-selling HCV drug in the world, as well as today's announcement from Express Scripts that it has excluded MAVIRET from its HCV formulary for 2019.

As a preliminary matter, this announcement only affects the formulary for 2019, has no impact on MAVIRET access in 2018. More importantly, AbbVie has advised us that Express Scripts' sales represent only a small percentage of MAVIRET sales in the U.S. this year… AbbVie does not believe there will be any significant change in market access for MAVIRET in the U.S. in 2019 compared to 2018.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up